ASH 2023: Leukemias and MDS

CE / CME

Key Studies in Leukemias and Myelodysplastic Syndromes: Independent Conference Coverage of ASH 2023

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurses: 1.00 Nursing contact hour

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

Released: March 06, 2024

Expiration: March 05, 2025

Eunice S. Wang
Eunice S. Wang, MD

Activity

Progress
1 2
Course Completed

Introduction

In this module, Eunice S. Wang, MD, reviews key studies in acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute promyelocytic leukemia (APL), and myelodysplastic syndromes (MDS) presented at the 2023 American Society of Hematology (ASH) Annual Meeting and Exposition.

Please note that the key points discussed in this module are illustrated with thumbnails from accompanying downloadable PowerPoint slidesets, which can be found here or downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. A few questions will be asked twice: once at the beginning of the activity and then again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

For those providing patient care, how many patients with leukemia or MDS do you provide care for in a typical month?

At ASH 2023, which of the following was reported in the phase I/II trial of induction and consolidation therapy with quizartinib in combination with venetoclax and decitabine for patients with AML harboring a FLT3-ITD mutation?

Which of the following results was reported for patients enrolled on the phase I/II AUGMENT-101 trial, which evaluated the safety and efficacy of revumenib, a menin inhibitor, in patients with R/R KMT2Ar acute leukemia?

The phase III IMerge trial evaluated the efficacy of imetelstat vs placebo in patients with lower-risk MDS who were red blood cell (RBC) transfusion dependent and refractory to or relapsed on erythropoiesis-stimulating agents (ESAs) or erythropoietin.

In the subgroup analysis according to risk category of the phase III IMerge trial presented at ASH 2023, which of the following best describes the patient population who showed improved RBC transfusion independence (RBC-TI) outcomes with imetelstat vs placebo?